USP37 directly deubiquitinates and stabilizes c-Myc in lung cancer

Oncogene

Volumn 34, Issue 30, 2015, Pages 3957-3967

  Pan, J ^a   Deng, Q ^a   Jiang, C ^a   Wang, X ^a   Niu, T ^a   Li, H ^a   Chen, T ^a   Jin, J ^a   Pan, W ^a   Cai, X ^b   Yang, X ^b   Lu, M ^c   Xiao, J ^b   Wang, P ^a,c  

^a EAST CHINA NORMAL UNIVERSITY   (China)

^b SECOND MILITARY MEDICAL UNIVERSITY   (China)

^c TONGJI UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOHEXIMIDE; DEUBIQUITINASE; GLUCOSE TRANSPORTER 1; MESSENGER RNA; MYC PROTEIN; UBIQUITIN PROTEIN LIGASE E3; UBIQUITIN SPECIFIC PROTEASE 37; UNCLASSIFIED DRUG; DEUBIQUITINASE USP37, HUMAN; MYC PROTEIN, HUMAN; PROTEINASE;

ARTICLE; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; ENZYME ACTIVITY; GENE INTERACTION; GENE OVEREXPRESSION; GLUCOSE INTAKE; GLUCOSE TRANSPORT; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOPRECIPITATION; IN VITRO STUDY; LUCIFERASE ASSAY; LUNG CANCER; ONCOGENE C MYC; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN INTERACTION; PROTEIN PHOSPHORYLATION; UBIQUITINATION; UPREGULATION; WESTERN BLOTTING; ADENOCARCINOMA; ENZYMOLOGY; GLYCOLYSIS; HEK293 CELL LINE; HELA CELL LINE; LUNG TUMOR; METABOLISM; PHYSIOLOGY; PROTEIN STABILITY;

ADENOCARCINOMA; CELL PROLIFERATION; ENDOPEPTIDASES; GLYCOLYSIS; HEK293 CELLS; HELA CELLS; HUMANS; LUNG NEOPLASMS; PROTEIN STABILITY; PROTO-ONCOGENE PROTEINS C-MYC; UBIQUITINATION;

EID: 84937966446     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2014.327     Document Type: Article

References (45)

1. Hershko A, Ciechanover A. The ubiquitin system. Annu Rev Biochem 1998; 67: 425-479.
2. Rotin D, Kumar S. Physiological functions of the HECT family of ubiquitin ligases. Nat Rev Mol Cell Biol 2009; 10: 398-409.
3. Amerik AY, Hochstrasser M. Mechanism and function of deubiquitinating enzymes. Biochim Biophys Acta 2004; 1695: 189-207.
4. Nijman SMB, Luna-Vargas MPA, Velds A, Brummelkamp TR, Dirac AMG, Sixma TK et al. A genomic and functional inventory of deubiquitinating enzymes. Cell 2005; 123: 773-786.
5. Sacco JJ, Coulson JM, Clague MJ, Urbé S. Emerging roles of deubiquitinases in cancer-associated pathways. IUBMB Life 2010; 62: 140-157 NA-NA.
6. Todi SV, Paulson HL. Balancing act: deubiquitinating enzymes in the nervous system. Trends Neurosci 2011; 34: 370-382.
7. Yuan J, Luo K, Zhang L, Cheville JC, Lou Z. USP10 regulates p53 localization and stability by deubiquitinating p53. Cell 2010; 140: 384-396.
8. Sheng Y, Saridakis V, Sarkari F, Duan S, Wu T, Arrowsmith CH et al. Molecular recognition of p53 and MDM2 by USP7/HAUSP. Nat Struct Mol Biol 2006; 13: 285-291.
9. Song MS, Salmena L, Carracedo A, Egia A, Lo-Coco F, Teruya-Feldstein J et al. The deubiquitinylation and localization of PTEN are regulated by a HAUSP-PML network. Nature 2008; 455: 813-817.
10. Zhang J, Zhang P, Wei Y, Piao HL, Wang W, Maddika S et al. Deubiquitylation and stabilization of PTEN by USP13. Nat Cell Biol 2013; 15: 1486-1494.
11. Lin Z, Yang H, Kong Q, Li J, Lee SM, Gao B et al. USP22 antagonizes p53 transcriptional activation by deubiquitinating Sirt1 to suppress cell apoptosis and is required for mouse embryonic development. Mol Cell 2012; 46: 484-494.
12. Liu J, Xia H, Kim M, Xu L, Li Y, Zhang L et al. Beclin1 controls the levels of p53 by regulating the deubiquitination activity of USP10 and USP13. Cell 2011; 147: 223-234.
13. Song MS, Salmena L, Carracedo A, Egia A, Lo-Coco F, Teruya-Feldstein J et al. The deubiquitinylation and localization of PTEN are regulated by a HAUSP-PML network. Nature 2008; 455: 813-817.
14. Dang CV, O'Donnell KA, Zeller KI, Nguyen T, Osthus RC, Li F. The c-Myc target gene network. Semin Cancer Biol 2006; 16: 253-264.
15. Larsson L-G, Henriksson MA. The Yin and Yang functions of the Myc oncoprotein in cancer development and as targets for therapy. Exp Cell Res 2010; 316: 1429-1437.
16. Soga T. Cancer metabolism: key players in metabolic reprogramming. Cancer Sci 2013; 104: 275-281.
17. DeBerardinis RJ, Lum JJ, Hatzivassiliou G, Thompson CB. The biology of cancer: metabolic reprogramming fuels cell growth and proliferation. Cell Metab 2008; 7: 11-20.
18. Dang CV, Kim JW, Gao P, Yustein J. The interplay between MYC and HIF in cancer. Nat Rev Cancer 2008; 8: 51-56.
19. Oster SK, Ho CS, Soucie EL, Penn LZ. The myc oncogene: MarvelouslY complex. Adv Cancer Res 2002; 84: 81-154.
20. Salghetti SE, Young Kim S, Tansey WP. Destruction of Myc by ubiquitin-mediated proteolysis: cancer-associated and transforming mutations stabilize Myc. EMBO J 1999; 18: 717-726.
21. Welcker M, Orian A, Jin J, Grim JA, Harper JW, Eisenman RN et al. The Fbw7 tumor suppressor regulates glycogen synthase kinase 3 phosphorylationdependent c-Myc protein degradation. Proc Natl Acad Sci USA 2004; 101: 9085-9090.
22. Von Der Lehr N, Johansson S, Wu S, Bahram F, Castell A, Cetinkaya C et al. The F-box protein Skp2 participates in c-Myc proteosomal degradation and acts as a cofactor for c-Myc-regulated transcription. Mol Cell 2003; 11: 1189-1200.
23. Hart M, Concordet J, Lassot I, Albert I, Del los Santos R, Durand H et al. The F-box protein-TrCP associates with phosphorylated-catenin and regulates its activity in the cell. Curr Biol 1999; 9: 207-211.
24. Popov N, Schülein C, Jaenicke LA, Eilers M. Ubiquitylation of the amino terminus of Myc by SCF [beta]-TrCP antagonizes SCFFbw7-mediated turnover. Nat Cell Biol 2010; 12: 973-981.
25. Paul I, Ahmed SF, Bhowmik A, Deb S, Ghosh MK. The ubiquitin ligase CHIP regulates c-Myc stability and transcriptional activity. Oncogene 2013; 32: 1284-1295.
26. Schwamborn JC, Berezikov E, Knoblich JA. The TRIM-NHL protein TRIM32 activates microRNAs and prevents self-renewal in mouse neural progenitors. Cell 2009; 136: 913-925.
27. Choi SH, Wright JB, Gerber SA, Cole MD. Myc protein is stabilized by suppression of a novel E3 ligase complex in cancer cells. Genes Dev 2010; 24: 1236-1241.
28. Adhikary S, Marinoni F, Hock A, Hulleman E, Popov N, Beier R et al. The ubiquitin ligase HectH9 regulates transcriptional activation by Myc and is essential for tumor cell proliferation. Cell 2005; 123: 409-421.
29. Popov N, Wanzel M, Madiredjo M, Zhang D, Beijersbergen R, Bernards R et al. The ubiquitin-specific protease USP28 is required for MYC stability. Nat Cell Biol 2007; 9: 765-774.
30. Welcker M, Clurman BE. FBW7 ubiquitin ligase: A tumour suppressor at the crossroads of cell division, growth and differentiation. Nat Rev Cancer 2008; 8: 83-93.
31. Welcker M, Orian A, Jin J, Grim JE, Harper JW, Eisenman RN et al. The Fbw7 tumor suppressor regulates glycogen synthase kinase 3 phosphorylationdependent c-Myc protein degradation. Proc Natl Acad Sci USA 2004; 101: 9085-9090.
32. Yada M, Hatakeyama S, Kamura T, Nishiyama M, Tsunematsu R, Imaki H et al. Phosphorylation-dependent degradation of c-Myc is mediated by the F-box protein Fbw7. EMBO J 2004; 23: 2116-2125.
33. Herbst A, Salghetti SE, Kim SY, Tansey WP. Multiple cell-type-specific elements regulate Myc protein stability. Oncogene 2004; 23: 3863-3871.
34. Hsu PP, Sabatini DM. Cancer cell metabolism: Warburg and beyond. Cell 2008; 134: 703-707.
35. Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours. Nature 2012; 490: 61-70.
36. Seo HR, Kim J, Bae S, Soh JW, Lee YS. Cdk5-mediated phosphorylation of c-Myc on Ser-62 is essential in transcriptional activation of cyclin B1 by cyclin G1. J Biol Chem 2008; 283: 15601-15610.
37. von der Lehr N, Johansson S, Wu S, Bahram F, Castell A, Cetinkaya C et al. The F-box protein Skp2 participates in c-Myc proteosomal degradation and acts as a cofactor for c-Myc-regulated transcription. Mol Cell 2003; 11: 1189-1200.
38. Kim SY, Herbst A, Tworkowski KA, Salghetti SE, Tansey WP. Skp2 regulates Myc protein stability and activity. Mol Cell 2003; 11: 1177-1188.
39. Huang X, Summers Matthew K, Pham V, Lill Jennie R, Liu J, Lee G et al. Deubiquitinase USP37 is activated by CDK2 to antagonize APCCDH1 and promote S phase entry. Mol Cell 2011; 42: 511-523.
40. Bianchi F, Nuciforo P, Vecchi M, Bernard L, Tizzoni L, Marchetti A et al. Survival prediction of stage I lung adenocarcinomas by expression of 10 genes. J Clin Invest 2007; 117: 3436-3444.
41. Yang WC, Shih HM. The deubiquitinating enzyme USP37 regulates the oncogenic fusion protein PLZF/RARA stability. Oncogene 2012; 32: 5167-5175.
42. Das CM, Taylor P, Gireud M, Singh A, Lee D, Fuller G et al. The deubiquitylase USP37 links REST to the control of p27 stability and cell proliferation. Oncogene 2012; 32: 1691-1701.
43. Li R, Wei J, Jiang C, Liu D, Deng L, Zhang K et al. Akt SUMOylation regulates cell proliferation and tumorigenesis. Cancer Res 2013; 73: 5742-5753.
44. Ning X, Hui L, Jian L, Rui W, Haiquan C, Jiquan C et al. Ubiquitin-specific protease 4 (USP4) targets TRAF2 and TRAF6 for deubiquitination and inhibits TNFalphainduced cancer cell migration. Biochem J 2012; 441: 979-986.
45. Liao P, Wang W, Shen M, Pan W, Zhang K, Wang R et al. A positive feedback loop between EBP2 and c-Myc regulates rDNA transcription, cell proliferation, and tumorigenesis. Cell Death Dis 2014; 5: e1032.